Welcome to the Pulmonary Hypertension Accelerated Bayer Awards website
Following the successful completion of the third year of the PHAB Awards program, we are delighted to announce that Letters of Intent (LOI) may be submitted to the program for the 2022 /2023 cycle. The deadline for submission of LOIs is 15th October 2022. For subsequent timelines click below and see section Dates and deadlines.
To apply for the PHAB Awards
Follow our step-by-step instructions to discover how to submit a proposal.
The program can collectively award a total of up to US$1 million in grants. The research project duration can extend over two years.
The PHAB Awards aim to support clinical research in pulmonary hypertension (PH) with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). All investigators, clinicians, and allied HCPs working within PH in the United States today may apply. The objectives of the program are to:
- Support continued advancement in PH science and care
- Contribute to the growing body of PH research seeking to improve patient outcomes